{
  "id": 13922425,
  "title": "Why is BioMarin Pharmaceutical stock gaining today?",
  "url": "https://urgent.news/2026/10/12/why-is-biomarin-pharmaceutical-stock-gaining-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-12T09:40:25.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-biomarin-pharmaceutical-stock-gaining-today-93CH-4943646"
  },
  "original_language": "en",
  "account": null,
  "summary": "BioMarin Pharmaceutical's stock saw a 1.0% increase in pre-open trading today, reaching $55.32, following Bank of America Securities analyst Jason Gerberry's reaffirmation of a Buy rating on the shares. Despite lingering uncertainty around Voxzogo’s patent landscape, Gerberry maintained his $80 price target. The reaffirmation was timely, coming ahead of regular trading, and was supported by BioMarin presenting data from 13 research studies at the American Society for Bone and Mineral Research Annual Meeting in Boston. The data included post-hoc analyses showing Voxzogo’s impact on critical skull growth regions in infants and young children with achondroplasia. Additionally, BioMarin disclosed it has filed with the FDA for a Voxzogo label expansion into hypochondroplasia, with a potential 2027 launch. The broader market was calm, with the S&P 500 up 0.1% and the Nasdaq essentially flat, providing a supportive backdrop for the stock-specific catalysts.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}